Boston Scientific’s MedSurg business going strong in fiscal 2018
In Q2 2018, Boston Scientific’s (BSX) MedSurg sales grew ~10.4% YoY (year-over-year) to $751 billion, contributing ~30% of the company’s total sales. Its MedSurg operational revenue grew ~9% in Q2 2018, compared with ~7.4% in Q1 2018.
In the second quarter, the MedSurg segment saw strong growth in its Endoscopy and Urology & Pelvic Health divisions, with Endoscopy sales growing ~8.9% (compared with ~6.2% in Q2 2017) and Urology & Pelvic Health sales growing 9.1%.
BSX’s Endoscopy business
In Q2 2018, Boston Scientific’s Endoscopy sales grew 10.6% YoY to $442 million, and its operational revenue grew ~8.9%. The division continued to be driven by its pathology and infection prevention businesses, Spyglass DS visualization platform, Resolution 360 hemostasis clip, and Axios stent. Going forward, Boston Scientific expects its therapeutic imaging platform to double its Endoscopy revenue by 2021. In the next article, we’ll discuss the key drivers of the MedSurg segment’s Urology & Pelvic Health division.
Check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend information. Take a look!